LENZ Therapeutics (LENZ) Research & Development (2020 - 2025)
LENZ Therapeutics (LENZ) posted quarterly Research & Development of $3.8 million for Q3 2025, down 41.23% year-over-year from $6.5 million in Q3 2024, and down 58.16% quarter-over-quarter from $9.1 million in Q2 2025.
LENZ Therapeutics (LENZ) Research & Development (2020 - 2025) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Research & Development for 6 consecutive years, with $3.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Research & Development fell 41.23% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $12.9 million (down 48.76% YoY), while the FY2025 annual figure was $18.7 million, down 37.35% from the prior year.
- Research & Development slipped to $3.8 million in Q3 2025 per LENZ's latest filing, from $9.1 million in the prior quarter.
- Across five years, Research & Development topped out at $19.5 million in Q4 2023 and bottomed at $3.8 million in Q3 2025.
- Historically, Research & Development has averaged $11.5 million across 5 years, with a median of $10.5 million in 2024.
- Annual changes were most pronounced in 2021 — Research & Development surged 16623.88% — and 2024, when it sank 69.96%.
- LENZ Therapeutics' Research & Development stood at $11.2 million in 2021, then soared by 64.77% to $18.5 million in 2022, then advanced by 5.82% to $19.5 million in 2023, then tumbled by 69.96% to $5.9 million in 2024, then tumbled by 35.4% to $3.8 million in 2025.
- Business Quant data shows LENZ's Research & Development at $3.8 million in Q3 2025, $9.1 million in Q2 2025, and $5.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 9.06 Mn |
| Mar 31, 2025 | 5.82 Mn |
| Dec 31, 2024 | 5.87 Mn |
| Sep 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | 10.54 Mn |
| Dec 31, 2023 | 19.54 Mn |
| Sep 30, 2023 | 17.00 Mn |
| Jun 30, 2023 | 12.64 Mn |
| Mar 31, 2023 | 10.33 Mn |
| Dec 31, 2022 | 18.46 Mn |
| Sep 30, 2022 | 18.30 Mn |
| Jun 30, 2022 | 17.78 Mn |
| Mar 31, 2022 | 18.25 Mn |
| Dec 31, 2021 | 11.21 Mn |
| Sep 30, 2021 | 8.68 Mn |
| Jun 30, 2021 | 12.67 Mn |
| Mar 31, 2021 | 5.38 Mn |
| Dec 31, 2020 | 67,000.00 |